Evidence map›Paper›PMID 40978011›Full record

ArticleInternational journal of pharmaceutics: X2025

MgZnFe-layered double hydroxides as a dual-function platform for enhancing subunit vaccine efficacy in tumor immunotherapy.

Xue Wang, Lu Liu, Yingying Chen, Lirui Jia, Yongjun Wang, Wei Jing, Guangqi Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xue WangSchool and Hospital of Stomatology, Liaoning Provincial Key laboratory of Oral Diseases, China Medical University, Shenyang 110101, China.
Lu LiuSchool and Hospital of Stomatology, Liaoning Provincial Key laboratory of Oral Diseases, China Medical University, Shenyang 110101, China.
Yingying ChenDepartment of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110022, China.
Lirui JiaWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yongjun WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wei JingDepartment of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110001, China.
Guangqi YanSchool and Hospital of Stomatology, Liaoning Provincial Key laboratory of Oral Diseases, China Medical University, Shenyang 110101, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic cancer vaccines show promise in immunotherapy but face challenges such as poor antigen delivery, insufficient immune activation, and an immunosuppressive tumor microenvironment, limiting tumor-specific cellular immunity. In this study, we present a dual-function tumor vaccine platform, MgFeZn-Layered double hydroxide (LMFZ), serving as both an antigen delivery system and immune adjuvant to enhance antitumor responses. Loaded with antigens, nanometer-sized LMFZ particles efficiently traffic to lymph nodes, promoting antigen capture by dendritic cells (DCs). LMFZ endosomal escape enables antigen cross-presentation and enhances DC maturation, boosting cytotoxic T lymphocyte proliferation and tumor infiltration. LMFZ also neutralizes tumor acidity, induces M1 polarization of macrophage, and enhances natural killer cell activity via Zn

Indexed as

Cancer vaccineCross-presentationEndosome lysisLayered double hydroxideLymph nodes targeting

Identifiers

PMID40978011
PMCPMC12445715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.